| Primary |
| Product Used For Unknown Indication |
33.3% |
| Colitis Ulcerative |
12.8% |
| Cytomegalovirus Infection |
12.8% |
| Cervix Carcinoma |
5.1% |
| Diabetes Mellitus |
5.1% |
| Fungal Infection |
5.1% |
| Cytomegalovirus Chorioretinitis |
2.6% |
| Cytomegalovirus Colitis |
2.6% |
| Cytomegalovirus Enteritis |
2.6% |
| Cytomegalovirus Enterocolitis |
2.6% |
| Cytomegalovirus Test Positive |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Gastrooesophageal Reflux Disease |
2.6% |
| Neutrophil Count Decreased |
2.6% |
| Systemic Lupus Erythematosus |
2.6% |
| Urinary Tract Infection |
2.6% |
|
| White Blood Cell Count Decreased |
16.7% |
| Altered State Of Consciousness |
11.1% |
| Bone Marrow Failure |
11.1% |
| Hypoglycaemia |
11.1% |
| Agranulocytosis |
5.6% |
| Cytomegalovirus Enteritis |
5.6% |
| Drug-induced Liver Injury |
5.6% |
| Hyponatraemia |
5.6% |
| Neutrophil Count Decreased |
5.6% |
| Pancytopenia |
5.6% |
| Pneumonia Cytomegaloviral |
5.6% |
| Psychiatric Symptom |
5.6% |
| Pyrexia |
5.6% |
|
| Secondary |
| Infection Prophylaxis |
14.4% |
| Renal Transplant |
14.4% |
| Lung Transplant |
11.1% |
| Prophylaxis |
10.4% |
| Hiv Infection |
9.2% |
| Pneumonia |
5.9% |
| Prophylaxis Against Graft Versus Host Disease |
5.9% |
| Mycosis Fungoides |
4.4% |
| Cytomegalovirus Infection |
3.9% |
| Product Used For Unknown Indication |
3.7% |
| Graft Versus Host Disease |
2.2% |
| Bone Marrow Conditioning Regimen |
1.8% |
| Rheumatoid Arthritis |
1.8% |
| Packed Red Blood Cell Transfusion |
1.7% |
| Platelet Transfusion |
1.7% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Convulsion Prophylaxis |
1.5% |
| Cytomegalovirus Chorioretinitis |
1.5% |
| Mycobacterium Avium Complex Infection |
1.5% |
| Pneumonia Bacterial |
1.5% |
|
| Renal Impairment |
16.7% |
| White Blood Cell Count Decreased |
15.6% |
| Platelet Count Decreased |
13.3% |
| Cytomegalovirus Infection |
6.7% |
| Sepsis |
5.6% |
| Vomiting |
5.6% |
| Viral Haemorrhagic Cystitis |
4.4% |
| Liver Disorder |
3.3% |
| Pancytopenia |
3.3% |
| Renal Failure |
3.3% |
| Thrombocytopenia |
3.3% |
| Bone Marrow Failure |
2.2% |
| Neutrophil Count Decreased |
2.2% |
| Oral Mucosal Disorder |
2.2% |
| Pneumocystis Jiroveci Pneumonia |
2.2% |
| Rectal Perforation |
2.2% |
| Staphylococcal Sepsis |
2.2% |
| Venoocclusive Liver Disease |
2.2% |
| Weight Increased |
2.2% |
| Hepatic Failure |
1.1% |
|
| Concomitant |
| Infection Prophylaxis |
16.1% |
| Prophylaxis |
16.1% |
| Product Used For Unknown Indication |
11.1% |
| Drug Use For Unknown Indication |
9.9% |
| Renal Transplant |
6.6% |
| Prophylaxis Against Graft Versus Host Disease |
5.5% |
| Hiv Infection |
5.2% |
| Prophylaxis Against Transplant Rejection |
3.7% |
| Immunosuppression |
3.1% |
| Cytomegalovirus Infection |
3.0% |
| Infection |
2.7% |
| Allogenic Bone Marrow Transplantation Therapy |
2.6% |
| Multiple Myeloma |
2.3% |
| Hypertension |
2.1% |
| Pyrexia |
2.0% |
| Pneumonia |
1.7% |
| Acute Myeloid Leukaemia |
1.6% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Graft Versus Host Disease |
1.6% |
| Insomnia |
1.4% |
|
| White Blood Cell Count Decreased |
12.4% |
| Sepsis |
10.1% |
| Renal Impairment |
7.9% |
| Thrombotic Microangiopathy |
6.7% |
| Interstitial Lung Disease |
5.6% |
| Thrombocytopenia |
5.6% |
| Viral Infection |
5.6% |
| Drug Eruption |
4.5% |
| Pneumonia |
4.5% |
| Respiratory Failure |
4.5% |
| Transfusion Microchimerism |
4.5% |
| Death |
3.4% |
| Red Blood Cell Count Decreased |
3.4% |
| Renal Failure |
3.4% |
| Renal Failure Acute |
3.4% |
| Scedosporium Infection |
3.4% |
| Staphylococcal Sepsis |
3.4% |
| Venoocclusive Liver Disease |
3.4% |
| Encephalitis Cytomegalovirus |
2.2% |
| Granulocyte Count Decreased |
2.2% |
|
